Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives (Q38685278)

5 September 2017

1 reference

title

Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives (English)

1 reference

5 September 2017

1 reference

Matthew S Farina

1

1 reference

5 September 2017

Kevin T Lundgren

series ordinal

2

1 reference

5 September 2017

Joaquim Bellmunt

series ordinal

3

1 reference

5 September 2017

11 May 2017

1 reference

5 September 2017

1 reference

5 September 2017

77

1 reference

5 September 2017

1077-1089

1 reference

5 September 2017

10

1 reference

https://scigraph.springernature.com/pub.10.1007/s40265-017-0748-7

5 September 2017

0 references

cites work

Cancer Statistics, 2017.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0748-7

Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0748-7

First- and second-line therapy for metastatic urothelial carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0748-7

Bacillus Calmette-Guérin treatment of non-muscle invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0748-7

History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0748-7

A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0748-7

Camouflage and sabotage: tumor escape from the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0748-7

Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0748-7

Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0748-7

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0748-7

CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0748-7

Anti-PD-1 and PD-L1 therapy for bladder cancer: what is on the horizon?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0748-7

Balance of CD8+ CD28+ / CD8+ CD28- T lymphocytes is vital for patients with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0748-7

CD8+CD28- regulatory T lymphocytes prevent experimental inflammatory bowel disease in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0748-7

CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0748-7

The role of the CD28 receptor during T cell responses to antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0748-7

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0748-7

Molecular interactions mediating T cell antigen recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0748-7

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0748-7

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0748-7

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0748-7

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0748-7

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0748-7

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0748-7

Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0748-7

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0748-7

Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0748-7

Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0748-7

Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0748-7

Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0748-7

Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0748-7

Comprehensive molecular characterization of urothelial bladder carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0748-7

Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0748-7

Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0748-7

Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy

21 January 2018

1 reference

12 December 2020

Immunotherapy of guinea pig cancer with BCG.

1 reference

12 December 2020

Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study

1 reference

12 December 2020

A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy

1 reference

12 December 2020

CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression

1 reference

12 December 2020

Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European

1 reference

12 December 2020

Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. 1976.

1 reference

12 December 2020

10.1007/S40265-017-0748-7

Identifiers

DOI

1 reference

Dimensions Publication ID

5 September 2017

0 references

1 reference